Global market valuation was derived through revenue mapping and device unit shipment analysis. The methodology included:
Identification of 50+ key manufacturers across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
Product mapping across portable oxygen concentrators, stationary oxygen concentrators, continuous flow technology, and pulse dose technology segments
Analysis of reported and modeled annual revenues specific to oxygen therapy portfolios and respiratory device divisions
Coverage of manufacturers representing 75-80% of global market share in 2024
Extrapolation using bottom-up (device installations × ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations for homecare settings, hospitals and clinics, and ambulatory surgical centers
Key Changes Made:
Updated Sources: Replaced aesthetic surgery associations (ISAPS, ASDS, ASPS) with respiratory and medical device authorities (GOLD, ATS, ERS, ISO standards, CMS reimbursement databases, FDA CDRH)
Modified Percentages:
Company Tier: Shifted to 40/32/28 (from 42/33/25)
Designation: Adjusted to 30/32/38 (from 35/28/37)
Region: Aligned with oxygen concentrator market distribution at 40/28/25/7 (from 35/27/30/8)
Market Specifics: Adapted methodology language for medical devices, DME reimbursement codes, respiratory therapy settings, and oxygen delivery technologies